Everything you need to win Portal — in one platform.
Who to reach, what to say, and why now on Portal — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.
Get the full Deep Dive on Portal — free.
One free Deep Dive, emailed to you. No spam; unsubscribe anytime.
Portal Biotechnologies has secured an $8M contract with DARPA for the RBC Factory Program to develop a portable cell therapy device. This initiative seeks to enhance personalized medical interventions by enabling rapid modifications of red blood cells at the point of care.
Company Information
Company
Portal
Location
Arlington, Massachusetts, United States
About
Portal is a cell engineering platform company focused on enabling next generation cell engineering and cell analytics across research and clinical applications. We are implementing a simplified approach to intracellular delivery, focused on accelerating advances enabled by the new generation of RNA, gene editing, and AI-driven technologies. Portal’s initial product suite is based on a proprietary mechanical delivery system capable of delivering many different types of cargo to a broad range of cell types. The technology's ability to be used stand-alone or as an integrated component of third-party systems provides a significant opportunity to broadly impact the fields of biological research and cellular therapeutics
ArlingtonBiotechnologyArtificial Intelligence